Abstract:Developing Bruton's tyrosine kinase (BTK) inhibitors has become a significant focus in recent years because BTK inhibition is an effective approach for the treatment of B-cell malignancies. For covalent BTK inhibitors, low oral bioavailability and low kinase selectivity remain unaddressed issues; thus, more diverse inhibitors with both novel structures and selective on target binding profiles are still needed. Here, four key regions where inhibitors bind to BTK were identified by analyzing the existing crystal structures of BTK complexes. Then, a scaffold-based molecular design work flow was established by integrating fragment-growing method, deep learning-based framework XGraphBoost and molecular docking, leading to four compounds that showed potency against BTK. Optimization of compounds 1 and 2 led to the discovery of the potent BTK inhibitor compound 42 by using in vitro potency and pharmacokinetic (PK) studies to prioritize the compounds. Compound 42 exhibited great BTK inhibition activity (IC50 = 0.7 nM) along with high oral absorption. Moreover, 42 demonstrated excellent kinase selectivity, especially over EGFR kinase, and low toxicity. In a TMD8 xenograft model, 42 significantly inhibited tumor growth (TGI = 104%) at a dosage of 50 mg/kg, indicating its potential as a novel therapeutic option for B-cell lymphomas.

Discovery and Structure-Activity Relationship of Novel Diphenylthiazole Derivatives As BTK Inhibitor with Potent Activity Against B Cell Lymphoma Cell Lines.

Design, Synthesis and Biological Evaluation of Novel 2-Phenyl Pyrimidine Derivatives As Potent Bruton's Tyrosine Kinase (BTK) Inhibitors.

Discovery and Biological Evaluation of N5-substituted 6,7-Dioxo-6,7-dihydropteridine Derivatives As Potent Bruton's Tyrosine Kinase Inhibitors.

Discovery and Biological Evaluation of Pyrimido[4,5-D]pyrimidine-2,4(1h,3h)-dione Derivatives As Potent Bruton’s Tyrosine Kinase Inhibitors

Discovery of new BTK inhibitors with B cell suppression activity bearing a 4,6-substituted thieno[3,2-d]pyrimidine scaffold

Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines As Novel Bruton’s Tyrosine Kinase Inhibitors

Discovery of Pyrido[3,4-B]indol-1-one Derivatives As Novel Non-Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors.

Design, Synthesis and Biological Evaluation of Novel 3-Substituted Pyrazolopyrimidine Derivatives As Potent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Novel 6-Amino-1,3,5-triazine Derivatives As Potent BTK Inhibitors: Structure-Activity Relationship (SAR) Analysis and Preliminary Mechanism Investigation.

Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.

Discovery of Potent and Highly Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Bearing Triazine Scaffold.

Structure-activity Relationship Investigation for Benzonaphthyridinone Derivatives As Novel Potent Bruton's Tyrosine Kinase (BTK) Irreversible Inhibitors.

Structure-based Discovery of Novel 4,5,6-Trisubstituted Pyrimidines As Potent Covalent Bruton’s Tyrosine Kinase Inhibitors

Discovery of Pteridine-7(8H)-one Derivatives As Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK).

Discovery of Pyrrolo[1,2-A]quinoxalin-4(5h)-one Derivatives As Novel Non-Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Design, Synthesis and Biological Evaluation of Novel Dithiocarbamate-Substituted Diphenylaminopyrimidine Derivatives As BTK Inhibitors

Discovery of Thieno[3,2-C]pyridin-4-amines As Novel Bruton's Tyrosine Kinase (BTK) Inhibitors.

Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors

Discovery of Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors Bearing a Pyrrolo[2,3-D]pyrimidine Scaffold

Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.